Large-scale trials have also observed development of SAMS in statin intolerant patients randomized to either PCSK9 inhibitors and/or ezetimibe, drugs that operate via mechanisms distinct to statins (35, 36). Here, PCSK9 is linked to short stature-auditory canal atresia-mandibular hypoplasia-skeletal anomalies syndrome.